Sight Sciences Inc (SGHT) - Total Liabilities
Based on the latest financial reports, Sight Sciences Inc (SGHT) has total liabilities worth $51.97 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sight Sciences Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Sight Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Sight Sciences Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Sight Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Sight Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
USA | $2.49 Billion |
|
TruBridge Inc.
NASDAQ:TBRG
|
USA | $219.05 Million |
|
enCore Energy Corp. Common Shares
NYSE MKT:EU
|
USA | $164.15 Million |
|
SilverBox Corp V
NYSE:SBXE
|
USA | $20.31 Million |
|
Linhai Co Ltd
SHG:600099
|
China | CN¥713.06 Million |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
China | CN¥45.68 Million |
|
Singaraja Putra
JK:SINI
|
Indonesia | Rp2.05 Trillion |
|
Nongshim Holdi
KO:072710
|
Korea | ₩518.33 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Sight Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sight Sciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sight Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sight Sciences Inc (2018–2024)
The table below shows the annual total liabilities of Sight Sciences Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $55.32 Million | +19.12% |
| 2023-12-31 | $46.44 Million | -12.38% |
| 2022-12-31 | $53.00 Million | +10.23% |
| 2021-12-31 | $48.08 Million | -70.26% |
| 2020-12-31 | $161.66 Million | +89.24% |
| 2019-12-31 | $85.42 Million | +130.53% |
| 2018-12-31 | $37.06 Million | -- |
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeo… Read more